Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Evaluation of a community pharmacy-based influenza and group A streptococcal pharyngitis disease management program using polymerase chain reaction point-of-care testing.

Klepser DG, Klepser ME, Murry JS, Borden H, Olsen KM.

J Am Pharm Assoc (2003). 2019 Nov - Dec;59(6):872-879. doi: 10.1016/j.japh.2019.07.011. Epub 2019 Aug 29.

PMID:
31474527
2.

Pharmacy-based management of influenza: lessons learned from research.

Klepser ME, Adams AJ.

Int J Pharm Pract. 2018 Dec;26(6):573-578. doi: 10.1111/ijpp.12488. Epub 2018 Sep 28.

PMID:
30265414
3.

The Roles of Pharmacy Schools in Bridging the Gap Between Law and Practice.

Adams AJ, Dering-Anderson A, Klepser ME, Klepser D.

Am J Pharm Educ. 2018 May;82(4):6577. doi: 10.5688/ajpe6577. Review.

4.

Point-of-care testing in the pharmacy: how is the field evolving?

Klepser DG, Klepser ME.

Expert Rev Mol Diagn. 2018 Jan;18(1):5-6. doi: 10.1080/14737159.2018.1392240. Epub 2017 Oct 19. No abstract available.

PMID:
29034791
5.

Observation of a Pharmacist-Conducted Group A Streptococcal Pharyngitis Point-of-Care Test: A Time and Motion Study.

Corn CE, Klepser DG, Dering-Anderson AM, Brown TG, Klepser ME, Smith JK.

J Pharm Pract. 2018 Jun;31(3):284-291. doi: 10.1177/0897190017710518. Epub 2017 May 28.

PMID:
28553774
6.

Outpatient antibiotic stewardship: Interventions and opportunities.

Dobson EL, Klepser ME, Pogue JM, Labreche MJ, Adams AJ, Gauthier TP, Turner RB, Su CP, Jacobs DM, Suda KJ; SIDP Community Pharmacy Antimicrobial Stewardship Task Force.

J Am Pharm Assoc (2003). 2017 Jul - Aug;57(4):464-473. doi: 10.1016/j.japh.2017.03.014. Epub 2017 May 16. Review.

PMID:
28526402
7.

A call to action for outpatient antibiotic stewardship.

Klepser ME, Dobson EL, Pogue JM, Labreche MJ, Adams AJ, Gauthier TP, Turner RB, Su CP, Jacobs DM, Suda KJ; SIDP Community Pharmacy Antimicrobial Stewardship Task Force.

J Am Pharm Assoc (2003). 2017 Jul - Aug;57(4):457-463. doi: 10.1016/j.japh.2017.03.013. Epub 2017 May 9.

PMID:
28499717
8.

Utilization of influenza and streptococcal pharyngitis point-of-care testing in the community pharmacy practice setting.

Klepser DG, Klepser ME, Smith JK, Dering-Anderson AM, Nelson M, Pohren LE.

Res Social Adm Pharm. 2018 Apr;14(4):356-359. doi: 10.1016/j.sapharm.2017.04.012. Epub 2017 May 2.

PMID:
28479019
9.

Community pharmacy-based point-of-care testing: A case study of pharmacist-physician collaborative working relationships.

Bacci JL, Klepser D, Tilley H, Smith JK, Klepser ME.

Res Social Adm Pharm. 2018 Jan;14(1):112-115. doi: 10.1016/j.sapharm.2016.12.005. Epub 2017 Jan 3.

PMID:
28082033
10.

Potential for Pharmacy-Public Health Collaborations Using Pharmacy-Based Point-of-Care Testing Services for Infectious Diseases.

Gubbins PO, Klepser ME, Adams AJ, Jacobs DM, Percival KM, Tallman GB.

J Public Health Manag Pract. 2017 Nov/Dec;23(6):593-600. doi: 10.1097/PHH.0000000000000482. Review.

PMID:
27997479
11.

A systematic review of rapid diagnostic tests for influenza: considerations for the community pharmacist.

Koski RR, Klepser ME.

J Am Pharm Assoc (2003). 2017 Jan - Feb;57(1):13-19. doi: 10.1016/j.japh.2016.08.018. Review. Erratum in: J Am Pharm Assoc (2003). 2018 Jan - Feb;58(1):128.

PMID:
27836481
12.

An update on community pharmacies as CLIA-waived facilities.

Adams AJ, Klepser ME, Klepser D.

Res Social Adm Pharm. 2016 Jul-Aug;12(4):666-7. doi: 10.1016/j.sapharm.2016.03.007. Epub 2016 Apr 6. No abstract available.

PMID:
27138067
13.

Community pharmacist-physician collaborative streptococcal pharyngitis management program.

Klepser DG, Klepser ME, Dering-Anderson AM, Morse JA, Smith JK, Klepser SA.

J Am Pharm Assoc (2003). 2016 May-Jun;56(3):323-329.e1. doi: 10.1016/j.japh.2015.11.013. Epub 2016 Apr 7.

PMID:
27067554
14.

Effectiveness of a pharmacist-physician collaborative program to manage influenza-like illness.

Klepser ME, Klepser DG, Dering-Anderson AM, Morse JA, Smith JK, Klepser SA.

J Am Pharm Assoc (2003). 2016 Jan;56(1):14-21. doi: 10.1016/j.japh.2015.11.008.

PMID:
26802915
15.

Use of CLIA-waived point-of-care tests for infectious diseases in community pharmacies in the United States.

Weber NC, Klepser ME, Akers JM, Klepser DG, Adams AJ.

Expert Rev Mol Diagn. 2016;16(2):253-64. doi: 10.1586/14737159.2015.1116388. Epub 2015 Nov 27. Review.

PMID:
26560318
16.

U.S. community pharmacies as CLIA-waived facilities: Prevalence, dispersion, and impact on patient access to testing.

Klepser ME, Adams AJ, Srnis P, Mazzucco M, Klepser D.

Res Social Adm Pharm. 2016 Jul-Aug;12(4):614-21. doi: 10.1016/j.sapharm.2015.09.006. Epub 2015 Sep 28.

PMID:
26508268
17.

Health Care Resource Utilization and Costs for Influenza-like Illness Among Midwestern Health Plan Members.

Klepser DG, Corn CE, Schmidt M, Dering-Anderson AM, Klepser ME.

J Manag Care Spec Pharm. 2015 Jul;21(7):568-73.

18.

Antimicrobial stewardship in outpatient settings: leveraging innovative physician-pharmacist collaborations to reduce antibiotic resistance.

Klepser ME, Adams AJ, Klepser DG.

Health Secur. 2015 May-Jun;13(3):166-73. doi: 10.1089/hs.2014.0083.

PMID:
26042860
19.

Pharmacist-provided rapid HIV testing in two community pharmacies.

Darin KM, Klepser ME, Klepser DE, Klepser SA, Reeves A, Young M, Scarsi KK.

J Am Pharm Assoc (2003). 2015 Jan-Feb;55(1):81-8. doi: 10.1331/JAPhA.2015.14070.

PMID:
25415222
20.

Consumer interest in community pharmacy HIV screening services.

Darin KM, Scarsi KK, Klepser DG, Klepser SA, Reeves A, Young M, Klepser ME.

J Am Pharm Assoc (2003). 2015 Jan-Feb;55(1):67-72. doi: 10.1331/JAPhA.2015.14069.

PMID:
25414989
21.

Socioeconomic impact of seasonal (epidemic) influenza and the role of over-the-counter medicines.

Klepser ME.

Drugs. 2014 Sep;74(13):1467-79. doi: 10.1007/s40265-014-0245-1. Review.

22.

Point-of-care testing for infectious diseases: opportunities, barriers, and considerations in community pharmacy.

Gubbins PO, Klepser ME, Dering-Anderson AM, Bauer KA, Darin KM, Klepser S, Matthias KR, Scarsi K.

J Am Pharm Assoc (2003). 2014 Mar-Apr;54(2):163-71. doi: 10.1331/JAPhA.2014.13167. Review.

PMID:
24632931
23.

Cost-effectiveness of pharmacist-provided treatment of adult pharyngitis.

Klepser DG, Bisanz SE, Klepser ME.

Am J Manag Care. 2012 Apr 1;18(4):e145-54.

PMID:
22554040
24.

Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.

Zoller E, Valente C, Baker K, Klepser ME.

Drug Des Devel Ther. 2010 Nov 4;4:299-311. doi: 10.2147/DDDT.S7773. Review.

25.

Influenza vaccination rates among pharmacists.

Ruiz AD, Frei CR, Barner JC, Carson JJ, Oramasionwu CU, Ruiz JL, Daniels KR, Mohr JF, Klepser ME.

J Am Pharm Assoc (2003). 2010 Jul-Aug;50(4):517-22. doi: 10.1331/JAPhA.2010.09146.

PMID:
20621870
26.

Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists.

Le J, Ashley ED, Neuhauser MM, Brown J, Gentry C, Klepser ME, Marr AM, Schiller D, Schwiesow JN, Tice S, VandenBussche HL, Wood GC; Society of Infectious Diseases Pharmacists Aerosolized Antimicrobials Task Force.

Pharmacotherapy. 2010 Jun;30(6):562-84. doi: 10.1592/phco.30.6.562.

PMID:
20500046
27.

Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis.

Daddario MK, Hagerman JK, Klepser ME.

Infect Drug Resist. 2010;3:123-32. doi: 10.2147/IDR.S7838. Epub 2010 Oct 28.

28.

Recommendations for training and certification for pharmacists practicing, mentoring, and educating in infectious diseases pharmacotherapy.

Ernst EJ, Klepser ME, Bosso JA, Rybak MJ, Hermsen ED, Segarra-Newnham M, Drew RH.

Pharmacotherapy. 2009 Apr;29(4):482-8. doi: 10.1592/phco.29.4.482.

PMID:
19323625
29.

Seasonal and pandemic influenza: preparing pharmacists for the frontline.

Klepser ME.

J Am Pharm Assoc (2003). 2008 Mar-Apr;48(2):312-4. doi: 10.1331/JAPhA.2008.08508. No abstract available.

PMID:
18359736
30.

Safety of aerosolized amphotericin B.

Knechtel SA, Klepser ME.

Expert Opin Drug Saf. 2007 Sep;6(5):523-32. Review.

PMID:
17877440
31.

Tobramycin solution for inhalation in cystic fibrosis patients: a review of the literature.

Hagerman JK, Knechtel SA, Klepser ME.

Expert Opin Pharmacother. 2007 Mar;8(4):467-75. Review.

PMID:
17309341
32.

Pertussis resurgence: diagnosis, treatment, prevention, and beyond.

Raguckas SE, VandenBussche HL, Jacobs C, Klepser ME.

Pharmacotherapy. 2007 Jan;27(1):41-52. Review.

PMID:
17192161
33.

International adoption: issues in infectious diseases.

Staat DD, Klepser ME.

Pharmacotherapy. 2006 Sep;26(9):1207-20. Review.

PMID:
16945042
34.

Candida resistance and its clinical relevance.

Klepser ME.

Pharmacotherapy. 2006 Jun;26(6 Pt 2):68S-75S. Review.

PMID:
16716125
35.

Aerosolised antibiotics: a critical appraisal of their use.

Hagerman JK, Hancock KE, Klepser ME.

Expert Opin Drug Deliv. 2006 Jan;3(1):71-86. Review.

PMID:
16370941
36.
37.

Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?

Vandenbussche HL, Klepser ME.

Lancet. 2005 Feb 12-18;365(9459):547-8. No abstract available.

PMID:
15708080
38.

Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model.

Shah NP, Reddy P, Paladino JA, McKinnon PS, Klepser ME, Pashos CL.

Curr Med Res Opin. 2004 Jun;20(6):779-90.

PMID:
15200734
39.

Role of nebulized antibiotics for the treatment of respiratory infections.

Klepser ME.

Curr Opin Infect Dis. 2004 Apr;17(2):109-12. Review.

PMID:
15021049
40.

Health care resource utilization associated with treatment of penicillin-susceptible and -nonsusceptible isolates of Streptococcus pneumoniae.

Klepser ME, Klepser DG, Ernst EJ, Brooks J, Diekema DJ, Mozaffari E, Hendrickson J, Doern GV.

Pharmacotherapy. 2003 Mar;23(3):349-59.

PMID:
12627934
41.

Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model.

Hoffman HL, Klepser ME, Ernst EJ, Petzold CR, Sa'adah LM, Doern GV.

Antimicrob Agents Chemother. 2003 Feb;47(2):739-46.

42.

In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies.

Ernst EJ, Roling EE, Petzold CR, Keele DJ, Klepser ME.

Antimicrob Agents Chemother. 2002 Dec;46(12):3846-53.

43.
44.
45.

The rationale for aerosolized antibiotics.

Flume P, Klepser ME.

Pharmacotherapy. 2002 Mar;22(3 Pt 2):71S-79S. Review.

PMID:
11898884
46.

The dynamics of health care resource utilization.

Klepser ME, Klepser DG.

Pharmacotherapy. 2002 Feb;22(2 Pt 2):39S-44S.

PMID:
11837546
47.

Amphotericin B in lung transplant recipients.

Klepser ME.

Ann Pharmacother. 2002 Jan;36(1):167-9.

PMID:
11816247
48.
50.

Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology.

Keele DJ, DeLallo VC, Lewis RE, Ernst EJ, Klepser ME.

Diagn Microbiol Infect Dis. 2001 Nov;41(3):121-6.

PMID:
11750164

Supplemental Content

Loading ...
Support Center